MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI
Pharmaceutical Preparations · CIK 0001823239 · Fiscal year ends 1231
Revenue
$185.74M
Fiscal year ended 2025-12-31Operating income
-$215.27M
Fiscal year ended 2025-12-31Free cash flow
-$70.72M
Fiscal year ended 2025-12-31Valuation, from the filing
| Public float | $300.00M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|
| Float / revenue | 1.6× | A lower bound on the multiple, because affiliate holdings are excluded. |
|---|
| Float / equity | 0.8× | A lower bound on the multiple, because affiliate holdings are excluded. |
|---|
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) reported revenue of $185.74M and net income of -$130.77M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from MARAVAI LIFESCIENCES HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
MARAVAI LIFESCIENCES HOLDINGS, INC. income by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|
| Revenue | $185.74M | $259.18M | $288.94M | $883.00M | $799.24M | $284.10M | $143.14M |
|---|
| Cost of revenue | $151.75M | $150.88M | $148.74M | $168.96M | $140.56M | $79.65M | $66.85M |
|---|
| Gross profit | $33.99M | $108.31M | $140.20M | $714.04M | $658.68M | $204.45M | $76.29M |
|---|
| Operating income | -$215.27M | -$235.62M | -$31.65M | $574.22M | $554.64M | $119.90M | $23.99M |
|---|
| Net income | -$130.77M | -$144.85M | -$119.03M | $220.20M | $182.04M | $88.97M | -$4.47M |
|---|
| Research & development | $17.40M | $19.22M | $17.28M | $18.37M | $15.22M | $9.30M | $3.63M |
|---|
| Weighted-average diluted shares | shares 144.36M | shares 137.91M | shares 131.92M | shares 255.32M | shares 257.80M | shares 28.91M | shares 253.92M |
|---|
| Pretax income | -$234.97M | -$261.48M | $617.74M | $551.47M | $530.76M | $81.70M | -$5.85M |
|---|
| Income tax expense | -$4.21M | -$1.86M | $756.11M | $60.81M | $61.52M | $2.88M | -$652.00K |
|---|
| Diluted EPS | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.56 | $2.36 | $-0.03 |
|---|
| Selling, general & administrative | $145.12M | $161.77M | $151.39M | $129.26M | $100.06M | $94.24M | $48.35M |
|---|
| General & administrative | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Selling & marketing | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Balance
MARAVAI LIFESCIENCES HOLDINGS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|
| Cash & equivalents | $216.89M | $322.40M | $574.96M | $632.14M | —Unavailable | —Unavailable | —Unavailable |
|---|
| Total assets | $770.58M | $1.01B | $1.49B | $2.28B | $1.92B | $1.27B | —Unavailable |
|---|
| Current assets | $296.25M | $429.15M | $699.91M | $847.90M | $740.04M | $331.60M | —Unavailable |
|---|
| Total liabilities | $397.87M | $431.04M | $697.57M | $1.38B | $1.37B | $1.12B | —Unavailable |
|---|
| Current liabilities | $44.92M | $56.97M | $87.47M | $110.14M | $93.78M | $130.78M | —Unavailable |
|---|
| Total equity incl. NCI | $372.71M | $577.21M | $789.88M | $905.24M | $545.36M | $154.75M | $144.63M |
|---|
| Temporary (mezzanine) equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Inventory | $40.50M | $50.08M | $51.40M | $43.15M | $51.56M | $33.30M | —Unavailable |
|---|
| Accounts receivable | $25.50M | $38.52M | $54.60M | $138.62M | $117.51M | $51.02M | —Unavailable |
|---|
| Goodwill | $129.43M | $159.88M | $326.03M | $283.67M | $152.77M | $224.28M | —Unavailable |
|---|
| Long-term debt | $286.33M | $290.49M | $518.71M | $522.00M | $524.59M | $528.61M | —Unavailable |
|---|
| Accounts payable | $2.91M | $11.96M | —Unavailable | $5.99M | $8.15M | $8.17M | —Unavailable |
|---|
Cash flow
Derived
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MRVI in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.